Appointment

PROTEOME SCIENCES plc                             

                                 PRESS RELEASE                                 

For immediate release 18th July, 2006

                          PROTEOME SCIENCES APPOINTS                           

                           CHIEF SCIENTIFIC OFFICER                            

Proteome Sciences plc ("Proteome Sciences" or "the Company") is pleased to
announce that Dr. Peter Schulz-Knappe will join the Company on 1st August, 2006
as Research and Development Director/CSO. Dr. Schulz-Knappe will be splitting
his responsibilities between the Company's Head Office in Cobham and its
laboratories in Frankfurt and London.

Prior to its takeover by Digilab LLC in February 2006, Dr. Schulz-Knappe was
CSO and founder of BioVision GmbH ("BioVision"), a company that has used mass
spectrometry to quantify and sequence biomarkers in pharmacogenomics and
personalised medicine through differential peptide display (peptidomics).

Formally Head of the Department at the Lower Saxony Institute of Peptide
Chemistry, Dr. Schulz-Knappe worked in cell biology and peptide and protein
related science for 20 years and established a large network within the pharma,
diagnostics and biotech industries. These have included strategic research
alliances with many majors including Abbott, Novartis, Novo Nordisk, Astra
Zeneca and Roche.

Commenting on the appointment of Dr. Schulz-Knappe, Christopher Pearce, Chief
Executive of Proteome Sciences said:

"We are delighted that Dr. Schulz-Knappe will be joining us at this exciting
stage of our development. Having recently entered into licences for our stroke
biomarkers with two of the top ten global clinical diagnostic companies in high
throughput screening, we are keen to expand the coverage to the other main
players and to conclude similar agreements from our burgeoning portfolio of
biomarkers in neurodegenerative disorders, cancer and kidney transplant
rejection.

The recent signals from the US FDA of its intention to widen the scope of
biomarker data for new drug applications is a significant and positive shift
which should accelerate the pace of completion of other external licences and
further increase confidence in our future prospects."

Notes to editors:

Proteome Sciences plc

Proteome Sciences, a global leader in applied proteomics, uses high sensitivity
proprietary technologies to detect differentially expressed proteins in
diseases. The protein biomarkers discovered in body fluids or tissues are
validated, developed and commercialised as diagnostic, prognostic or
therapeutic products through strategic alliances and out-licensing.

Through its unique ProteoSHOP® toolbox, Proteome Sciences provides high
sensitivity/high throughput proteomics solutions, including traditional two
dimensional gel-based electrophoresis (2DE) and proprietary gel-free protein
sequence tag technologies (PST®, qPST™& TMT®), to major pharma, biotechnology
and diagnostic companies, to discover and exploit protein biomarkers.
Sensitizer® chemical mass tags have been developed separately as a series of
stand-alone reagents.

For further information please visit www.proteomics.com .

Enquiries:

Proteome Sciences plc

Christopher Pearce, Chief Executive Officer

Email: [e-mail]

Tel: [phone]

Public Relations for Proteome Sciences

IKON Associates

Adrian Shaw

Tel: [phone]

Mobile: [phone]

Email: [e-mail]